EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 27 / No 11 (Novembre 2011) Med Sci (Paris), 27 11 (2011) 938-940 References
Free Access
Issue
Med Sci (Paris)
Volume 27, Number 11, Novembre 2011
Page(s) 938 - 940
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20112711008
Published online 30 November 2011
  1. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010 ; 6 : 193–201. [CrossRef] [PubMed] [Google Scholar]
  2. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 2010 ; 6 : 405–410. [CrossRef] [PubMed] [Google Scholar]
  3. Britschgi M, Olin CE, Johns HT, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci USA 2009 ; 106 : 12145–12150. [CrossRef] [Google Scholar]
  4. Kellner A, Matschke J, Bernreuther C, et al. Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 2009 ; 65 : 24–31. [CrossRef] [PubMed] [Google Scholar]
  5. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003 ; 112 : 415–422. [CrossRef] [PubMed] [Google Scholar]
  6. Gilman S, Koler M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005 ; 64 : 1553–1562. [CrossRef] [PubMed] [Google Scholar]
  7. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009 ; 73 : 2061–2070. [CrossRef] [PubMed] [Google Scholar]
  8. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010 ; 9 : 363–372. [CrossRef] [PubMed] [Google Scholar]
  9. Ethell DW, Shippy D, Cao C, et al. Aβ-specific T cells reverse cognitive decline and synaptic loss in Alzheimer’s mice. Neurobiol Dis 2006 ; 23 : 351–361. [CrossRef] [PubMed] [Google Scholar]
  10. Toly-Ndour C, Lui G, Nunes MM, et al. MHC-Independent genetic factors control the magnitude of CD4+T cell responses to amyloid-β peptide in mice through regulatory T-cell mediated inhibition. J Immunol 2011 ; 187 : 4492–4500. [CrossRef] [PubMed] [Google Scholar]
  11. Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer’s disease: evidence from genome-wide pathway analysis. J Alzheimer Dis 2010 ; 20 : 1107–1118. [CrossRef] [Google Scholar]
  12. Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010 ; 5 : e13950. [CrossRef] [PubMed] [Google Scholar]
  13. Reddy MM, Wilson R, Wilson J, et al. Identification of candidate IgG biomarkers for Alzheimer’s disease via combinatorial library screening. Cell 2011 ; 144 : 132–142. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.